mHsp70

Membrane Hsp70: Novel Biomarker

Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form of Heat Shock Protein 70 (mHsp70).

We have entered into an exclusive worldwide license with Multimmune GmbH of Munich, Germany for its clinical-stage NK Cell therapy, supported by a Companion Diagnostic (CDx), which targets cancer cells expressing membrane Hsp70.

Heat shock protein 70 (Hsp70) is a chaperone protein produced intracellularly by cells in response to exposure to stressful physiological conditions. Hsp70 has been discovered to be highly expressed on the cell membrane (mHsp70) of a variety of different cancer types, but not expressed highly on normal cells.

Metastatic cancers have the highest membrane Hsp70. Metastatic tumors are responsible for ~90% of cancer-related deaths.

Radiation and chemotherapy increases mHsp70 expression and renders tumors more sensitive to therapeutics targeting mHsp70

Alphageneron has entered into an exclusive worldwide license with Multimmune GmbH of Munich, Germany for its therapeutic and diagnostic technology targeting membrane Hsp70.